Uniportal robotic-assisted thoracic surgery (U-RATS) represents a recent evolution in minimally invasive lung resection, combining the single-incision philosophy with robotic technology. However, its perioperative safety and outcomes have not been clearly defined across published studies. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and a registered protocol. PubMed, Web of Science, and the Cochrane Library were searched for studies reporting perioperative outcomes of U-RATS for anatomic lung resection in adults. Primary outcomes included conversion rate, morbidity, and mortality. Secondary outcomes were operative time, estimated blood loss, length of hospital stay, and lymph node yield. Random-effects models were applied to pool estimates. Sixteen studies encompassing 579 patients were included. The pooled conversion rate was 1.34% (95% CI: 0.42–4.15%), with no observed heterogeneity. The pooled postoperative morbidity rate was 5.99% (95% CI: 4.46–7.91%), and the pooled mortality rate was 0.21% (95% CI: 0.07–0.64%). The pooled mean operative time was 171.3 min, the estimated blood loss was 51.9 mL, and the postoperative length of stay was 4.9 days. Across 11 studies, the pooled lymph node yield was 16.6 nodes (95% CI: 14.0–19.2; I² = 89.8%). Current evidence suggests that U-RATS is a safe and feasible approach for anatomic lung resection, with low conversion and complication rates and acceptable perioperative outcomes comparable to established minimally invasive techniques.
Polynucleotides (PNs) and polydeoxyribonucleotides (PDRNs) are increasingly used in regenerative dermatology; however, randomized evidence across skin rejuvenation, scar prevention, and wound healing has not been comprehensively synthesized. This systematic review evaluated randomized clinical trials investigating PN- and PDRN-based interventions in these indications. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched through January 2026. Seven randomized trials involving 183 participants met the inclusion criteria. Four studies evaluated skin rejuvenation, one postoperative scar prevention, and two wound-healing applications. Across studies, PN and PDRN therapies improved wrinkle-related outcomes, scar quality, wound-healing metrics, and patient-reported satisfaction. The most consistent benefits were observed in wound-healing settings, where PDRN accelerated re-epithelialization and shortened healing time compared with controls. No serious treatment-related adverse events were reported. Although findings support the regenerative potential of PN- and PDRN-based therapies across multiple dermatologic applications, the evidence base remains limited by small sample sizes, heterogeneous treatment protocols, and variable outcome measures. Larger, adequately powered randomized trials are needed to establish optimal clinical indications and treatment strategies.
Adhesive small bowel obstruction (aSBO) is a common cause of emergency surgical admission, and the optimal initial management between early surgery and conservative non-operative management (NOM) remains debated, particularly regarding recurrence and short-term safety. This systematic review aimed to evaluate short- and long-term outcomes of early operative management compared with conservative treatment for aSBO in adult and paediatric populations. A systematic search of MEDLINE, Embase, Scopus, and Cochrane CENTRAL was conducted from inception to 2025 in accordance with PRISMA guidelines. Nine studies were included. In stable adults, NOM was generally safe with comparable short-term complication and mortality rates to early surgery; however, prolonged delays following NOM failure were associated with increased morbidity and bowel resection. Long-term outcomes consistently favoured early operative management, demonstrating a 40-60% relative reduction in recurrence. Water-soluble contrast protocols improved diagnostic accuracy and NOM success, while specific radiological findings predicted failure. In paediatric patients, NOM was effective in many cases, but infants under one year of age had a higher likelihood of requiring surgery, and delays beyond 48 hours increased bowel resection rates. Overall, NOM is safe for selected patients, but early surgery offers superior long-term recurrence outcomes.
adhesive small bowel obstructionearly surgical interventionconservative treatmentrecurrence
International Journal of Clinical Pediatric Dentistry · مجلد 19 (6) · 779-793
Background: Dental caries is a common oral health problem that affects people all over the world. To detect and treat it early on, it is important to have a thorough understanding of its genesis and potential biomarkers. Objective: The objective of this systematic review is to answer the question: "Is there any role of immune status in the development of dental caries among children and adults, and is there any potential in using immunological markers for diagnosis, prognosis, and treatment of this condition?" Design: From 2016 to 2024, a thorough search approach adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria was used across several datasets (PROSPERO: CRD42024612045). To find pertinent publications, a total of 2,723 articles were searched using keywords associated with dental caries, immunity, and interventions. The inclusion criteria included papers that addressed the connection between immunity and the development of caries, interventions, and results, including alterations in basal metabolic rate (BMR), weight gain in patients, improvements in quality of life, and recurrence of carious lesions. Two reviewers independently extracted the data, assessed its quality, and assessed the risk of bias using validated instruments such as the Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale. Results: The evaluation encompassed 10 articles in all, demonstrating noteworthy correlations between immunological indicators and dental caries. Results point to a favorable correlation between salivary immunoglobulin A (IgA) levels and the number of carious teeth, as well as an increase in proinflammatory cytokine concentrations in dental caries patients. Furthermore, the pulp tissue of dental caries patients has different bacterial communities and higher expression of proinflammatory cytokines, suggesting a possible connection between immune activation and dysbiosis. Conclusion: The findings highlight the significance of immune status/immunological indicators in the diagnosis and treatment of dental caries, emphasizing the necessity for additional study to corroborate these conclusions and improve treatment and preventative dental care practices. Clinical relevance: This work has got great relevance to pediatric dentists. The current work highlights a possible link between the immune status and the development of caries in pediatric and adult patients as well as the potential of immunological markers in the diagnosis, prognosis, and treatment of dental caries in both pediatric and adult patients. Prospero registration number: CRD42024612045.
Botulinum toxin type A (BoNT-A) injections have a well-known cosmetic outcome and safety profile in a variety of medical conditions. Recent studies have shown promising results for possible use in treating erythematotelangiectatic rosacea (ETR). This systematic review aimed to evaluate the efficacy and safety of BoNT-A injections in patients with ETR. A systematic search was conducted across multiple databases to identify relevant studies. Eligible articles were randomized controlled trials (RCTs) that investigated BoNT-A injections in adults diagnosed with ETR. Studies involving other rosacea subtypes, lacking a comparative group, or combining BoNT-A with other interventions without isolating its effects were excluded. Three RCTs met the inclusion criteria. Both parallel-group and split-face analyses demonstrated that BoNT-A injections significantly reduced facial erythema and flushing, resulting in improved patient satisfaction. Across all studies, BoNT-A was well-tolerated, with adverse events being mild, transient, and self-limited. However, the evidence remains limited by the small sample sizes, suboptimal study designs, and short follow-up durations. BoNT-A injections show promising efficacy and safety in the treatment of ETR. However, larger, well-designed randomized trials with longer follow-up durations are required to confirm its therapeutic role and establish standardized treatment protocols.
botulinum toxin type Aerythematotelangiectatic rosaceafacial erythemaflushing
Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.
Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.
ACE inhibitorsangiotensin receptor blockerstype 2 diabetesrenin-angiotensin-aldosterone system blockade
Indian Journal of Anaesthesia · مجلد 70 (1) · 79-91
Background and Aims: Laparoscopic cholecystectomy (LC) presents anaesthetic challenges such as haemodynamic instability and postoperative complications. Remimazolam (RMZ), a novel ultra-short acting benzodiazepine, has emerged as a promising alternative to the standard propofol, with a potentially superior safety profile. This study aimed to compare the efficacy and safety of RMZ with propofol for anaesthesia during LC. Methods: A systematic review and meta-analysis were conducted to synthesise evidence from randomised controlled trials (RCTs). A search of PubMed, Web of Science, Scopus, and Google Scholar through May 2025 was conducted. We pooled dichotomous outcomes using risk ratios (RRs) and continuous outcomes using mean differences (MDs), and 95% confidence intervals (CIs). Results: Six RCTs involving 452 patients were included in the analysis. Compared to the control group, RMZ was associated with a significantly longer anaesthesia onset time (MD: 13.26, 95% CI: 0.47, 26.05, P = 0.04), recovery time (MD: 2.72, 95% CI: 0.44, 5.01, P = 0.02), and postanaesthesia care unit (PACU) stay (MD: 5.54, 95% CI: 0.86, 10.22, P = 0.02). However, RMZ significantly reduced the incidence of injection pain (RR: 0.03, 95% CI: 0.01, 0.15, P < 0.001), and no significant differences were observed in surgery duration ( P = 0.30), extubation time ( P = 0.14), or the incidence of hypotension ( P = 0.15), bradycardia ( P = 0.13), or postoperative nausea and vomiting ( P = 0.67). Conclusion: With uncertain evidence, RMZ significantly prolonged anaesthesia onset time, recovery time, and time to PACU discharge compared to control in patients undergoing LC. Still, RMZ improved patient comfort through significantly decreased incidence of injection pain and is associated with a comparable haemodynamic safety profile to propofol.
Journal of Orthopaedic Surgery and Research · مجلد 21 (1)
BACKGROUND: Degenerative spondylolisthesis affects approximately 39 million patients worldwide. While consensus supports decompression with fusion for single-level pathology, optimal surgical approaches for multi-level disease remain disputed. Despite the frequency of this clinical presentation, evidence comparing outcomes between Single-Level versus Multi-Level interbody fusion procedures is surprisingly scarce. This study aims to determine how the level of interbody fusion extent impacts outcomes in patients undergoing lumbar fusion for degenerative spondylolisthesis. METHODS: Our systematic review methodology involved comprehensive database searches (Web of Science, Scopus, PubMed, and Cochrane Library) from inception through April 2025. Two independent reviewers performed article screening, data extraction, and quality assessment. Statistical analyses used R software (v4.4.2), with outcomes reported as risk ratios for categorical variables and mean differences for continuous measures (95% CI). The certainty of evidence was assessed using the GRADE approach. RESULTS: Our meta-analysis evaluated 10 studies (N = 1430 patients; 971 Single-Level, 366 Double-Level, 198 Multi-Level fusions). Single-Level procedures demonstrated 41% lower revision rates (RR = 0.59 [0.40-0.86], p = 0.007). Operative advantages included reduced surgical time (-60.73 min [- 80.89 to - 40.57], p < 0.001), blood loss (-286.99mL [- 496.71 to - 77.27], p = 0.007), and hospitalization (-1.22 days [- 2.09 to - 0.34], p = 0.006). Oswestry Disability Index (ODI) scores showed borderline improvement (-3.90 [- 7.89 to 0.10], p = 0.06). Screw loosening decreased by 84% (RR = 0.16 [0.08-0.34], p < 0.001). We observed no significant differences in lumbar lordosis (-0.01 [- 1.75 to 1.72], p = 0.99), infection rates (RR = 0.49 [0.19-1.25], p = 0.13), adjacent segment deterioration, vascular injuries, or dural tears. The certainty of evidence ranged from low to very low, and high heterogeneity was observed in perioperative outcomes. CONCLUSIONS: Single-level fusion may offer a more favorable perioperative profile than double- or multi-level constructs, including lower revision risk, shorter operative time, reduced blood loss, shorter hospitalization, and fewer screw loosening events in pooled analyses. However, complications did not differ significantly between groups. Given substantial heterogeneity for perioperative outcomes and generally low to very low certainty of evidence, these findings should be interpreted cautiously and individualized to patient pathology and surgical context.
Journal of Clinical Medicine · مجلد 15 (6) · 2114-2114
Background: C-reactive protein (CRP), a biomarker of systemic inflammation, has been implicated in adverse pregnancy and neonatal outcomes. However, the relationship between maternal CRP and neonatal complications remains unclear. We conducted a systematic review and meta-analysis to synthesize available evidence. Methods: We systematically searched PubMed, Scopus, Web of Science, and Cochrane Library up to July 2025 for observational studies reporting maternal CRP levels in relation to neonatal outcomes. Eligible outcomes included preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), and stillbirth. Random-effects models were used to calculate pooled standardized mean differences (SMD) or odds ratios (OR) with 95% confidence intervals (CI). Statistical heterogeneity was assessed using the I2 statistic. Results: The search yielded 6843 records, of which 42 studies (comprising 18,393 pregnant women) met the inclusion criteria. Maternal mean CRP levels were significantly higher in adverse pregnancy outcomes compared with controls (SMD = 0.39; 95% CI 0.08–0.70; p = 0.01; I2 = 96.6%). Elevated CRP was strongly associated with PTB (OR = 3.81; 95% CI 2.66–5.47; p < 0.001; I2 = 85%; n = 23) and LBW (OR = 2.34; 95% CI 1.35–4.03; p = 0.002; I2 = 84.2%; n = 7). No significant associations were observed for SGA (OR = 1.14; 95% CI 0.86–1.49; p = 0.36; I2 = 0%; n = 5) or stillbirth (OR = 1.89; 95% CI 0.92–3.90; p = 0.08; I2 = 44.9%; n = 4). Conclusion: Maternal CRP is significantly associated with increased risks of preterm birth and low birth weight but not with SGA or stillbirth. These findings support the role of systemic inflammation in adverse neonatal outcomes and highlight the need for prospective studies to clarify causal mechanisms and assess the clinical utility of CRP in pregnancy risk stratification.
Fibromyalgia causes symptoms like chronic widespread pain, fatigue, and cognitive difficulties, often alongside depression and chronic pain, complicating treatment. While selective serotonin reuptake inhibitors (SSRIs) are prescribed for fibromyalgia-related depression and pain, their effectiveness is unclear. This systematic review and meta-analysis evaluated SSRI efficacy in fibromyalgia patients with comorbid depression and chronic pain. This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Ovid, and Google Scholar. We included randomized controlled trials (RCTs) using formal fibromyalgia criteria and reporting depression or pain outcomes. Non-RCTs, studies with non-adults, or non-SSRI comparisons without isolating SSRI effects were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB-2) was used to assess the risk of bias in this study. Four reviewers independently screened titles and abstracts; four assessed full-texts with disagreements resolved by a senior reviewer. Outcome data were converted to mean change scores from baseline where not directly reported. The standardized mean difference (SMD) was used for the meta-analysis to pool data across different scales. Nine RCTs (n = 461 participants, predominantly female, mean ages across studies ranged from 32.7 to 52.9 years) were analyzed. Compared to placebo, SSRIs significantly reduced pain (eight RCTs, n = 421; SMD -0.53, 95% confidence interval (CI): -0.92 to -0.14, p = 0.007) and improved depression (six RCTs, n = 265; SMD -0.67, 95% CI: -1.14 to -0.20, p = 0.005). SSRIs also significantly improved quality of life (QOL) versus placebo (five RCTs, n = 301; SMD -0.30, 95% CI: -0.55 to -0.04, p = 0.02). Compared to other non-pharmacological interventions (acupuncture and aerobic exercise), SSRIs showed non-significant improvement in depression (two RCTs, n = 70; SMD -0.39, 95% CI: -1.32 to 0.54, p = 0.41). Common side effects included gastrointestinal issues, dry mouth, sedation, sexual dysfunction, and headaches; SSRI groups reported more adverse events and higher dropout rates. SSRIs showed statistically significant benefits for pain, depression, and QOL in fibromyalgia compared to placebo. However, the overall evidence quality was found to be very low to low due to heterogeneity and risk of bias. Future RCT designs should adhere to a strict methodology in order to strengthen the available evidence on the efficacy of SSRIs in treating fibromyalgia.
Avicenna Journal of Medicine · مجلد 16 (01) · 004-015
Globally, 1 in 10 children are impacted by war, with over 24,000 violations documented in 2020 alone. These children face persistent mental health challenges, including anxiety, depression, and posttraumatic stress disorder (PTSD). This systematic review evaluates current psychological interventions for war-affected children. Following PRISMA guidelines, 10 studies (2013-2021) from conflict zones in non-high-income countries were analyzed. Clinical interventions such as the Teaching Recovery Techniques (TRTs) are crucial; TRT is a low-cost intervention implementable by trained nonprofessionals under supervision. Findings revealed that TRT showed promise, especially when combined with parenting sessions, underscoring the importance of caregiver involvement. School-based programs were effective in addressing PTSD and anxiety symptoms, highlighting the key role of schools and trained teachers. Reading interventions improved affect recognition, and life-skills approaches enhanced social coping, but the most impactful strategies integrated caregivers. Successful interventions combined parental and community support, emphasizing cultural adaptation and individualized approaches for sustained mental health improvements.
war-affected childrenchild and adolescent mental healthpsychological interventionpost-traumatic stress disorder
Background: Fournier’s gangrene is a rapidly progressive infection requiring coordinated emergency diagnosis, resuscitation, antimicrobial treatment, and surgical source control. Early manifestations overlap with less severe perineal infections, creating substantial diagnostic uncertainty. This review examined diagnostic and management evidence relevant to emergency department practice. Methods: Publications available through 31/05/2026 were evaluated using an explicit clinical framework. Eleven original reports addressing imaging, prognostic assessment, surgical timing, antimicrobial duration, hyperbaric oxygen, wound management, and fecal diversion were summarized. Findings were synthesized narratively because study designs, treatment selection, and outcome definitions differed. Results: Computed tomography demonstrated anatomical disease extent, although imaging findings from confirmed cases did not establish diagnostic accuracy in unselected emergency populations. Prognostic scores identified physiological disturbance without replacing clinical assessment or operative diagnosis. Earlier debridement was associated with lower mortality, including mortality of 2.6% versus 27.7% for surgery within versus after twelve hours in one cohort. Shorter antimicrobial courses following source control were not associated with worse outcomes in a retrospective study. Hyperbaric oxygen, negative pressure wound therapy, and fecal diversion produced favorable findings in selected cohorts, with substantial uncertainty from nonrandom treatment allocation. Conclusions: Emergency management prioritizes early surgical involvement, immediate broad spectrum antimicrobials, physiological stabilization, and prompt debridement. Imaging and prognostic tools support decisions without postponing source control. Adjunctive interventions require individualized selection, while prospective comparative research remains essential for defining their benefits.
Fournier's gangreneperineal soft tissue infectionemergency department managementsurgical debridement
Background: Family physicians evaluate skin disorders associated with diagnostic delay, systemic deterioration, tissue destruction, or delayed cancer treatment. These presentations include suspected malignancy, severe drug reactions, and invasive infection, although their referral pathways differ, this review evaluated diagnostic and referral performance in these categories. Methods: Original studies published through 31 Jan 2026 were reviewed using predefined criteria. Patient-based investigations were separated from studies using standardized photographs or clinical vignettes, while cancer pathways were analyzed independently from same-day dermatologic emergencies. Results: Ten studies evaluated diagnostic classification, referral, excision decisions, or image-based recognition. Melanoma sensitivity in general practitioners was 29% in one comparative study, whereas another reported 66.7% sensitivity and 92.0% specificity for recognizing malignant lesions. Following training, dermoscopy increased referral sensitivity from 54.1% to 79.2% without reducing specificity. Sequential dermoscopy reduced excision or referral of suspicious lesions by 56.4%, whereas other diagnostic aids produced inconsistent effects. In an urgent-disease vignette study, family physicians recognized Stevens-Johnson syndrome in 71.4% and pemphigus vulgaris in 28.6% of responses. Conclusion: Diagnostic performance varied according to disease spectrum, clinical setting, physician experience, assessment method, and outcome definition. Training-supported dermoscopy improved selected cancer-triage outcomes, although benefits were not reproduced across all diagnostic technologies.
Background Early prophylactic low-dose hydrocortisone has been proposed to reduce inflammation and to compensate for relative adrenal insufficiency in extremely preterm infants. Its overall balance of benefit and risk remains uncertain. Objective To evaluate whether hydrocortisone initiated within the first 24–48 h after birth reduces bronchopulmonary dysplasia (BPD) and mortality in infants born before 30 weeks' gestation. Methods This systematic review and meta-analysis followed PRISMA 2020 guidance and was registered in PROSPERO. PubMed, Cochrane CENTRAL, Scopus, and Web of Science were searched from inception to May 2026. Eligible studies enrolled infants born before 30 weeks' gestation who received early prophylactic systemic hydrocortisone at a low dose. Low dose was defined as a starting dose of no more than 2.0 mg/kg/day, begun within 24–48 h of birth. The comparator was placebo or no hydrocortisone. Randomized and quasi-randomized trials, their follow-up reports, and comparative observational studies were eligible. Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs). Results Fourteen studies with 3,416 infants were included. Early hydrocortisone did not significantly improve survival without BPD at 36 weeks' postmenstrual age (RR: 1.07, 95% CI: 0.97–1.19, p = 0.18). It also did not significantly reduce BPD at 36 weeks (RR: 0.94, 95% CI: 0.85–1.04, p = 0.25) or mortality before discharge (RR: 1.07, 95% CI: 0.77–1.49, p = 0.69). The duration of respiratory support and the need for oxygen at discharge were similar between groups. Subgroup analyses suggested a possible benefit in infants exposed to chorioamnionitis and in those born before 26 weeks, but these findings were exploratory. Hydrocortisone increased the risk of late-onset sepsis (RR: 1.19, 95% CI: 1.05–1.35, p = 0.01). Gastrointestinal perforation, necrotizing enterocolitis, major neonatal morbidities, and the available neurodevelopmental outcomes did not differ significantly between groups. Conclusion Current evidence does not support the routine use of early prophylactic hydrocortisone in all extremely preterm infants. Adequately powered trials and individual patient data analyses are needed to identify the subgroups most likely to benefit and to clarify long-term safety. Systematic Review Registration https://www.crd.york.ac.uk/prospero/view/CRD420261402317 , PROSPERO CRD420261402317.